Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,605

Employees7,605

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,605

Employees7,605

BIIB Key Statistics

Market cap

17.43B

Market cap17.43B

Price-Earnings ratio

10.62

Price-Earnings ratio10.62

Dividend yield

—

Dividend yield—

Average volume

1.50M

Average volume1.50M

High today

$120.09

High today$120.09

Low today

$117.68

Low today$117.68

Open price

$118.40

Open price$118.40

Volume

1.35M

Volume1.35M

52 Week high

$238.00

52 Week high$238.00

52 Week low

$110.04

52 Week low$110.04

BIIB News

TipRanks 18h

Biogen downgraded to Hold from Buy at HSBC

HSBC downgraded Biogen (BIIB) to Hold from Buy with a price target of $118, down from $342. The firm cites the company’s negative pipeline updates combined with...

TipRanks 5d

Strategic Collaborations and Financial Adjustments Bolster Biogen’s Growth Potential: A Buy Rating Justified

William Blair analyst Myles Minter has maintained their bullish stance on BIIB stock, giving a Buy rating on April 21. Myles Minter’s rating is based on severa...

TipRanks 7d

Biogen’s Strategic Focus and Market Positioning Justify Hold Rating Amid Uncertainties

BTIG analyst Thomas Shrader has maintained their neutral stance on BIIB stock, giving a Hold rating on April 17. Thomas Shrader has given his Hold rating due t...

Analyst ratings

57%

of 37 ratings

Buy

43.2%

Hold

56.8%

Sell